Single dose bioequivalence study of α-methyldopa tablet formulations using a modified HPLC method

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 10, 2010, Pages 607-611

  Valizadeh, Hadi ^a,b   Nemati, Mahboob ^a,b   Hallaj Nezhadi, Somayeh ^c   Ansarin, Masood ^a   Zakeri Milani, Parvin ^b,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bioequivalence; CAS 555 30 6; Centrally acting antihypertensive agent; HPLC; Pharmacokinetics; methyldopa, bioavailability

Indexed keywords

CAS 555 30 6; METHYLDOPA; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; VALIDATION PROCESS;

EID: 78049335445     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296333     Document Type: Article

References (14)

1. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: The McGraw-Hill Companies; 2006.
2. Moffat AC, Osselton MD, Widdop B. Clarke's analysis of drugs and poisons. 3rd ed. London: Pharmaceutical Press; 2006.
3. Conner DP, Davit BM. Bioequivalence and drug product assessment, in vivo, in generic drug product development solid oral dosage forms. New York: Marcel Dekker; 2005.
4. Róna K, Ary K, Renczes G, Gachályi B, Grézal GY, Drabant S, et al. Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2001 Jan-Jun;26(1-2):25-30.
5. Rona K, Ary K, Gachalyi B, Klebovich I. Determination of alpha a -methyldopa from human olasma by validated high-performance liquid chromatographic method with fluorescence detection. J Chromatogr A. 1996;730:125-31. (Pubitemid 26141931)
6. Bahrami G, Kiani A, Mirzaeei SH. A rapid high performance liquid chromatographic determination of methyldopa in human serumwith fluorescence detection and alumina extraction: application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Mar;832(2):197-201. (Pubitemid 43339946)
7. Boroujerdi M. Pharmacokinetics: principles and application. 1st ed. New York: The McGraw-Hill Companies; 2002.
8. Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S, Nemati M. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneimittelforschung. 2009;59(8):429-32.
9. Valizadeh H, Barghi L, Jalilian H, Islambulchilar Z, Zakeri-Milani P. Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. Arzneimittelforschung. 2009;59(7):345-9.
10. Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Nemati M. Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. Arzneimittelforschung. 2010;60(2):76-80.
11. Asiri YA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, et al. Comparative bioavailability study of cefixime (equivalent to 5ml/mg) suspension (Winex vs. Suprax) in healthy male volunteers. Int J Clin Pharmacol Ther. 2005;43(10):499-504.
12. Schall R, Luus H. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol. 1992;17:2231-41.
13. Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008;58(2):97-100.
14. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products, General considerations. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (COER); July 2002 BP.